抄録
In Japan, the major transfusion-transmited diseases (TTD) is non-A, non-B hepatitis which develops at an incidence of 10-20%. Since November 1989, Japanese Red Cross Blood Center have screened donors for the anti-HCV (anti-C100-3) antibody.
The anti-HCV positive rate (5.6%) among donors with transfusion histories (A group) at the Japanese Red Cross Tokyo Metropolitan Blood Center was significantly higher (p<0.001) than that (0.93%) among all blood donors (B group). The both rates increased according to the age of the donors and the number of years after transfusions. However, there were no significant differences between the anti-HCV positive rate of the donors under 19 years of age in A group and that of all age stratified donors in B group, and between that of the donors under 39 years of age in A group and that of the donors over 50 years of age in B group. The donors passed over 20 years after their transfusions had significantly higher anti-HCV positivity than those intervened less than 20 years did (p<0.05).
These data suggest that deferral of donors having received blood from the paid donors before over 20 years (prior to 1968) can be recommended to reduce the risk of TTD.
